Literature DB >> 23736912

Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim.

Andrea Piccin1, Giovanni Amaddii1, Fabrizio Natolino2, Atto Billio1, Sergio Cortelazzo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23736912      PMCID： PMC3934226          DOI： 10.2450/2013.0289-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

Review 1.  Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.

Authors:  Katy L Cooper; Patrick Fitzgerald; Kerry Dillingham; Kawitha Helme; Ron Akehurst
Journal:  Int J Technol Assess Health Care       Date:  2012-07       Impact factor: 2.188

Review 2.  Carbamazepine-induced thrombocytopenia defined by a challenge test.

Authors:  T Ishikita; A Ishiguro; K Fujisawa; I Tsukimoto; T Shimbo
Journal:  Am J Hematol       Date:  1999-09       Impact factor: 10.047

3.  Pancytopenia associated with clonazepam.

Authors:  Marnelli A Bautista-Quach; Yu-Min Liao; Chung-Tsen Hsueh
Journal:  J Hematol Oncol       Date:  2010-07-14       Impact factor: 17.388

4.  Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Authors:  T Aoki; Y Harada; E Matsubara; T Suzuki; T Oyama; M Kasai; T Uchida; M Ogura
Journal:  J Clin Pharm Ther       Date:  2012-05-14       Impact factor: 2.512

Review 5.  Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy.

Authors:  E Wyllie; R Wyllie
Journal:  Epilepsia       Date:  1991       Impact factor: 5.864
  5 in total
  6 in total

1.  Immune thrombocytopenia successfully treated with eltrombopag following multiple therapies including romiplostim.

Authors:  Roberto Sartori; Laura Candiotto; Marco Ruggeri; Giuseppe Tagariello
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

2.  Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  Blood Transfus       Date:  2017-01-25       Impact factor: 3.443

3.  Reciprocal absence of cross-resistance between eltrombopag and romiplostim in two patients with refractory immune thrombocytopenic purpura.

Authors:  Laura Scaramucci; Marco Giovannini; Pasquale Niscola; Andrea Tendas; Alessio Perrotti; Paolo De Fabritiis
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 4.  Clinical indications for thrombopoietin and thrombopoietin-receptor agonists.

Authors:  Bernhard Wörmann
Journal:  Transfus Med Hemother       Date:  2013-09-11       Impact factor: 3.747

5.  Efficacy and safety of eltrombopag in adult refractory immune thrombocytopenia.

Authors:  Yeo-Kyeoung Kim; Seung-Sin Lee; Sung-Hoon Jeong; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Hyeoung-Joon Kim
Journal:  Blood Res       Date:  2015-03-24

6.  Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821).

Authors:  Vidya P Kumar; Gregory P Holmes-Hampton; Shukla Biswas; Sasha Stone; Neel Kamal Sharma; Bernadette Hritzo; Mary Guilfoyle; Gary Eichenbaum; Chandan Guha; Sanchita P Ghosh
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.996
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.